Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05369533 · ClinicalTrials.gov registry record · Phase 1
Dopaminergic Enhancement of Rehabilitation Therapy Early After Stroke
A Phase 1 study of Stroke, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT05369533: Completed Phase 1 study of Stroke, sponsored by University of California, Los Angeles.
NCT05369533 is a Phase 1 study of Stroke that has completed, run by University of California, Los Angeles. The registered enrollment target is 25 participants, below the 12,016-participant average among 454 other Stroke trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05369533, a Phase 1 study of Stroke, has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
This study explores the effects of telerehabilitation and a study medication on rehabilitation outcomes in patients with stroke resulting in arm weakness. Patients with arm weakness due to a stroke that happened in the past 30 days will be randomized into one of three groups: \[1\] TR and placebo (a sugar pill) on top of usual care; \[2\] TR and a medication (Sinemet 25/100) on top of usual care; \[3\] or usual care alone (no TR and no pill, but people in this group will be offered TR once the study is done). TR consists of 70 minutes/day of activities targeting arm function, 6 days a week for 6 weeks.
Primary Outcome
Measures arm function using a scale that runs from 0 to 57 points, with higher scores indicating greater arm function.
Conditions Studied
Interventions
- DRUG Placebo
- DEVICE Telerehabilitation
- DRUG Sinemet Pill
Study Locations (1)
California
- California Rehabilitation Institute - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2022-08-01 |
| Est. Completion | 2024-03-11 |
| Phase | Phase 1 |
What the finished NCT05369533 record still lists
NCT05369533 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 12,016-participant average among 454 other Stroke trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Stroke appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT05369533 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05369533 about?
NCT05369533 is a clinical study titled "Dopaminergic Enhancement of Rehabilitation Therapy Early After Stroke". This study explores the effects of telerehabilitation and a study medication on rehabilitation outcomes in patients with stroke resulting in arm weakness. Patients with arm weakness due to a stroke that happened in the past 30 days will be randomized into one of three groups: \[1\] TR and placebo (a...
What is the current status of trial NCT05369533?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2022-08-01. Estimated completion is 2024-03-11.
What conditions does trial NCT05369533 study?
This clinical trial studies the following conditions: Stroke.
What interventions are being tested in trial NCT05369533?
The interventions under investigation include: Placebo (DRUG), Telerehabilitation (DEVICE), Sinemet Pill (DRUG).
Who is sponsoring clinical trial NCT05369533?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05369533 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stroke
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05369533's enrollment target sits among peer trials
25 327th of 454 higher than 120 of 454 other Stroke trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Stroke trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Infliximab Therapy for Dolichoectactic Vertebrobasilar Aneurysms
RECRUITING · Phase 1
-
Hybrid Robot+FES Stroke Rehabilitation
RECRUITING · Phase 1
-
Vibrotactile Stimulation for Upper-Extremity Stroke Rehabilitation
RECRUITING · Phase 1
-
Facilitating Neuroplastic Changes of Acute Stroke Survivors
RECRUITING · Phase 1
-
Identifying Personalized Brain States Predicting Residual Corticospinal Tract Output After Stroke
RECRUITING · Phase 1
-
Accelerated rTMS vs. Sham for Stroke Apathy
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI